KAS
JAZZ icon

Kestra Advisory Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kestra Advisory Services’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-368
Closed -$62.6K – 3770
2025
Q4 		$62.6K Buy
+368
New +$56.4K ﹤0.01% 3796
2023
Q1 		– Sell
-2,821
Closed -$449K – 2198
2022
Q4 		$449K Buy
2,821
+674
+31% +$98.8K ﹤0.01% 1478
2022
Q3 		$286K Sell
2,147
-868
-29% -$132K ﹤0.01% 1623
2022
Q2 		$470K Buy
3,015
+608
+25% +$93.6K ﹤0.01% 1367
2022
Q1 		$375K Buy
2,407
+26
+1% +$3.77K ﹤0.01% 1463
2021
Q4 		$303K Sell
2,381
-714
-23% -$93.8K ﹤0.01% 1601
2021
Q3 		$403K Buy
3,095
+93
+3% +$14.1K ﹤0.01% 1503
2021
Q2 		$533K Buy
+3,002
New +$520K 0.01% 1253

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Kestra Advisory Services's JAZZ Position: Q1 2026 in Review

Kestra Advisory Services sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 368 shares — an estimated $62.6K sold.

Kestra Advisory Services first reported a position in JAZZ in Q2 2021 and held it in 8 quarters. The position peaked at $533K in Q2 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Kestra Advisory Services reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 368 Jazz Pharmaceuticals shares in Q1 2026, an estimated $62.6K.
  • Kestra Advisory Services first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Kestra Advisory Services's Jazz Pharmaceuticals position peaked at $533K in Q2 2021.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.